8-K: Glaukos Reports Record Q2 2025 Sales, Raises Full-Year Guidance Amid Strong Product Adoption

Glaukos Corporation announced record second quarter 2025 net sales of $124.1 million, a 30% year-over-year increase, and raised its full-year 2025 net sales guidance to $480 million to $486 million.

Summary

• Record net sales of $124.1 million in Q2 2025, increased 30% year-over-year on a reported basis and 29% on a constant currency basis, compared to $95.7 million in Q2 2024.
• Glaucoma net sales reached a record $103.5 million in Q2 2025, up 36% year-over-year.
• U.S. Glaucoma net sales were a record $72.3 million in Q2 2025, up 45% year-over-year, driven by iDose TR sales of approximately $31 million.
• International Glaucoma net sales were approximately $31.3 million, representing year-over-year growth of 20% on a reported basis, or 15% on a constant currency basis.
• Corneal Health net revenues were approximately $20.6 million, representing year-over-year growth of 4%, including U.S. Photrexa net sales of $17.9 million.
• Gross margin for Q2 2025 was approximately 78% (non-GAAP 83%), compared to 76% (non-GAAP 82%) in Q2 2024.
• GAAP net loss in Q2 2025 was $19.7 million, or ($0.34) per diluted share, significantly improved from a net loss of $50.5 million, or ($1.00) per diluted share, in Q2 2024.
• Non-GAAP net loss in Q2 2025 was $13.6 million, or ($0.24) per diluted share, compared to $26.3 million, or ($0.52) per diluted share, in Q2 2024.
• Ended Q2 2025 with approximately $278.6 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt.
• Full-year 2025 net sales guidance was raised to $480 million to $486 million, up from the previous range of $475 million to $485 million.

Sentiment

Score: 8

Explanation: The company reported strong financial results, including record sales and improved profitability metrics, and raised its full-year revenue guidance. Significant progress was made in key product commercialization (iDose TR) and pipeline development (Epioxa, iStent infinite). While there are some headwinds like increased SG&A and R&D expenses, and potential reimbursement challenges, the overall tone and performance indicate strong positive momentum and strategic execution.

Positives

• Achieved record net sales of $124.1 million in Q2 2025, representing a substantial 30% year-over-year increase (29% on a constant currency basis).
• Reported record Glaucoma net sales of $103.5 million in Q2 2025, demonstrating 36% year-over-year growth.
• U.S. Glaucoma net sales reached a record $72.3 million in Q2 2025, increasing 45% year-over-year, significantly driven by iDose TR sales of approximately $31 million.
• Improved GAAP gross margin to approximately 78% in Q2 2025 from 76% in Q2 2024, and non-GAAP gross margin to 83% from 82%.
• Reduced GAAP loss from operations to $22.7 million in Q2 2025 from $30.0 million in Q2 2024.
• Reduced non-GAAP loss from operations to $16.6 million in Q2 2025 from $23.7 million in Q2 2024.
• Significantly narrowed GAAP net loss to $19.7 million, or ($0.34) per diluted share, from $50.5 million, or ($1.00) per diluted share, in the prior year.
• Reduced non-GAAP net loss to $13.6 million, or ($0.24) per diluted share, from $26.3 million, or ($0.52) per diluted share, in the prior year.
• Raised full-year 2025 net sales guidance to a range of $480 million to $486 million, indicating strong confidence in continued growth.
• Successfully advanced commercial launch activities for iDose TR in the U.S., with positive clinical outcomes and product feedback from a growing number of cases and trained surgeons.
• Received EU Medical Device Registration (MDR) certification for iStent infinite and other leading trabecular micro-bypass MIGS technologies, enabling European launch plans.
• Announced FDA acceptance for review of NDA submission for Epioxa (Epi-on) and completed successful pre-approval inspection and productive post mid-cycle review meeting.
• Acquired Mobius Therapeutics, whose lead product Mitosol will solidify the supply chain for the PRESERFLO MicroShunt study and support broader late-stage glaucoma efforts.
• Maintained a strong cash position of approximately $278.6 million with no debt at the end of Q2 2025.

Negatives

• Selling, general and administrative (SG&A) expenses increased 26% to $83.4 million (non-GAAP 27% to $83.1 million) year-over-year, reflecting commercial and G&A investments and new product launch activities.
• Research and development (R&D) expenses increased 6% to $36.5 million year-over-year, reflecting continued investment in R&D programs.
• Corneal Health net revenues grew modestly at 4% year-over-year, impacted by the company's entry into the Medicaid Drug Rebate Program (MDRP).
• Anticipated increasing headwinds from the trialing of new competitive products in some major international markets as 2025 progresses.
• CMS's Proposed Rules for Calendar Year 2026 include proposed reductions in physician fee reimbursement for several Category 1 CPT codes across ophthalmology, including for cataract and surgical MIGS procedures.
• Headwinds within the U.S. Glaucoma stent business are associated with the final MIGS LCDs in 5 of the 7 MACs.
• Potential transient headwinds within the U.S. Corneal Health franchise are associated with the Photrexa to Epioxa transition following targeted approval.
• Continued estimated impact on U.S. Glaucoma volumes is related to professional fee reimbursement for combination-cataract trabecular bypass surgery versus other more invasive alternatives.
• The year-over-year growth tailwind associated with the new French Health Authority rebate agreement is sunsetting.
• Cash and cash equivalents, short-term investments, and restricted cash decreased by $24.8 million quarter-over-quarter due to operating expenses, working capital, a $12.6 million net payment for the Mobius acquisition, and a $16.6 million payment for the Aliso Viejo HQ building purchase.

Risks

• Ability to successfully commercialize iDose TR therapy.
• Impact of general macroeconomic conditions, including foreign currency fluctuations and future public health crises, on the business.
• Ability to continue generating sales of commercialized products and developing and commercializing additional products.
• Dependence on a limited number of third-party suppliers, some of which are single-source, for components of products.
• Occurrence of a crippling accident, natural disaster, or other disruption at the primary facility, which may materially affect manufacturing capacity and operations.
• Securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using iStent, iStent inject W, iAccess, iStent infinite, iDose TR, corneal cross-linking products, or other products in development.
• Compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid.
• Ability to properly train, and gain acceptance and trust from ophthalmic surgeons in the use of products.
• Compliance with federal, state, and foreign laws and regulations for the approval and sale and marketing of products and of manufacturing processes.
• Lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes.
• Risk of recalls or serious safety issues with products and the uncertainty of patient outcomes.
• Ability to protect information systems against cyber threats and cybersecurity incidents, and to comply with state, federal, and foreign data privacy laws and regulations.
• Ability to protect, and the expense and time-consuming nature of protecting intellectual property against third parties and competitors, and the impact of any claims for infringement or misappropriation of third-party intellectual property rights and any related litigation.
• Ability to service indebtedness.
• Global macroeconomic environment and associated uncertainties, which are difficult to predict.
• Ongoing conversations around tariff and geopolitical issues, despite minimal direct exposure, as tariff dynamics remain highly fluid.

Future Outlook

Glaukos expects continued strong growth driven by iDose TR adoption and broader Interventional Glaucoma initiatives globally. The company anticipates potential growing contributions from iDose TR and iStent infinite as reimbursement confidence and broader initiatives take hold. It also foresees potential transient headwinds in the U.S. Glaucoma stent business due to final MIGS LCDs and in U.S. Corneal Health from the Photrexa to Epioxa transition. The company is advancing a robust pipeline of novel, dropless platform technologies, including Epioxa, iDose TREX, iStent infinite, PRESERFLO MicroShunt, Retina XR, and iLution Blepharitis, with several key clinical and regulatory milestones expected in the near future.

Management Comments

• Our record second quarter results reflect a sustained growth acceleration in our business driven by successful global execution of our key strategic plans.
• We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
• Most importantly, clinical outcomes and product feedback from a growing number of cases and trained surgeons continue to be very positive and reaffirm our view that with the launch of iDose TR, we have the potential to reshape glaucoma management as we know it today.

Industry Context

Glaukos operates in the ophthalmic pharmaceutical and medical technology sector, focusing on glaucoma, corneal disorders, and retinal diseases. The company is a pioneer in Micro-Invasive Glaucoma Surgery (MIGS) and is advancing 'dropless' therapies, which aim to disrupt traditional treatment paradigms. The industry is seeing continued innovation in drug delivery and surgical techniques for chronic eye diseases. The company's strong performance in Glaucoma, particularly with iDose TR, indicates a successful market penetration strategy in a competitive landscape. The mention of 'new competitive products in some of our major international markets' suggests an evolving competitive environment. CMS's proposed rule changes for physician fee reimbursement highlight ongoing regulatory and reimbursement challenges common in the medical device and pharmaceutical industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison to industry standards. It mentions 'new competitive products' and 'Combo-cataract MIGS competition globally' but does not name specific competitors or their results.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and pipeline advancements, potentially leading to increased share value.
• Patients: Positive impact through the development and commercialization of novel, dropless therapies like iDose TR, iStent infinite, and Epioxa, designed to improve outcomes for chronic eye diseases.
• Ophthalmic Surgeons: Continued engagement and training for new products like iDose TR, enhancing their treatment options and potentially reshaping glaucoma management.
• Employees: Continued investment in R&D and commercial activities suggests stable to growing employment opportunities.
• Suppliers: Continued demand for components, though dependence on limited/single-source suppliers is a noted risk.
• Payors (Medicare/Medicaid): Ongoing discussions and proposed rule changes regarding reimbursement rates for procedures using Glaukos products, which could impact access and revenue.

Next Steps

• Host a conference call and simultaneous webcast on July 30, 2025, at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company's financial outlook.
• Continue to successfully advance execution of detailed launch plans for iDose TR.
• Continue to scale international infrastructure and increasingly drive MIGS forward as the standard of care in each region and major market.
• Focus on expanding access for keratoconus patients suffering from this rarely diagnosed disease.
• Advance preparatory planning for potential Epioxa FDA approval and commercial launch.
• Commence commercial launch activities for iStent infinite in key European markets at the upcoming ESCRS annual meeting in September 2025.
• Advance towards PDUFA date of October 20, 2025, for Epioxa.
• Advance patient enrollment in Phase 2b/3 clinical program for iDose TREX, the next-generation iDose therapy.
• Advance review and dialogue with the FDA for previously submitted labeling supplement for the re-administration of iDose TR.
• Advance various Phase 4 studies for iDose TR.
• Advance patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients.
• Advance 510(k) pivotal study for PRESERFLO MicroShunt.
• Advance patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401), with an open U.S. FDA IND.
• Advance Phase 2 clinical program for third-generation iLink therapy.
• Prepare to commence Phase 2 clinical trial for iLution Blepharitis by end of 2025.
• File Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, by August 11, 2025.

Key Dates

Recommendation

Glaukos reported exceptional Q2 2025 results, significantly exceeding prior year performance with record net sales and substantial improvements in net loss and EPS. The company's decision to raise its full-year revenue guidance signals strong confidence in its continued growth trajectory, particularly driven by the successful commercialization of iDose TR. The robust pipeline, with multiple products advancing through clinical trials and regulatory approvals (e.g., Epioxa's PDUFA date, iStent infinite EU launch), indicates strong future revenue potential and market leadership in innovative ophthalmic therapies. While increased operating expenses and potential reimbursement headwinds exist, the overall momentum, strategic acquisitions (Mobius Therapeutics), and strong cash position without debt position Glaukos for sustained long-term growth and market share expansion in a critical healthcare sector. This performance suggests the company is executing effectively on its strategic plans and is poised for continued outperformance.

Keywords

Glaukos, GKOS, ophthalmic, glaucoma, corneal disorders, retinal diseases, iDose TR, MIGS, iStent, Epioxa, Photrexa, PRESERFLO MicroShunt, Mitosol, medical technology, pharmaceutical, financial results, Q2 2025, net sales, revenue guidance, R&D pipeline, healthcare, medical devices